United States · Bill · HR
H.R. 4043 (117th)
Ensuring Patient Access to Critical Breakthrough Products Act of 2021
Introduced
22 June 2021
Last action
23 June 2021 · Referred
Status
Referred to the Subcommittee on Health.
Sponsors
Rep. DelBene, Suzan K. [D-WA-1], Rep. Walorski, Jackie [R-IN-2], Rep. Cárdenas, Tony [D-CA-29], Rep. Bilirakis, Gus M. [R-FL-12], Rep. Sewell, Terri A. [D-AL-7], Rep. Upton, Fred [R-MI-6], Rep. Suozzi, Thomas R. [D-NY-3], Rep. Houlahan, Chrissy [D-PA-6], Rep. Dunn, Neal P. [R-FL-2], Rep. Bera, Ami [D-CA-6], Rep. McGovern, James P. [D-MA-2], Rep. Boyle, Brendan F. [D-PA-2], Rep. Correa, J. Luis [D-CA-46], Rep. Wenstrup, Brad R. [R-OH-2], Rep. Crenshaw, Dan [R-TX-2], Rep. Schrier, Kim [D-WA-8], Rep. Wild, Susan [D-PA-7], Rep. Pappas, Chris [D-NH-1], Rep. Peters, Scott H. [D-CA-50], Rep. Craig, Angie [D-MN-2], Rep. McKinley, David B. [R-WV-1], Rep. Kelly, Mike [R-PA-16], Rep. Lieu, Ted [D-CA-36], Rep. Aguilar, Pete [D-CA-33], Rep. Cheney, Liz [R-WY-At Large], Rep. Emmer, Tom [R-MN-6], Rep. Miller, Carol D. [R-WV-1], Rep. Steel, Michelle [R-CA-48], Rep. Dean, Madeleine [D-PA-4], Rep. Smucker, Lloyd [R-PA-11], Rep. Joyce, John [R-PA-13], Rep. Smith, Jason [R-MO-8], Rep. Lamb, Conor [D-PA-17], Rep. Auchincloss, Jake [D-MA-4]
Subjects
Healthcare
Source updated
3 January 2025
Summary
Ensuring Patient Access to Critical Breakthrough Products Act of 2021 This bill provides for Medicare coverage of medical devices that are approved under the Food and Drug Administration (FDA) Breakthrough Devices Program. (Under the program, manufacturers work with the FDA to expedite the review and approval of certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human diseases or conditions.) The bill allows designated medical breakthrough devices to be temporarily covered under Medicare during a four-year transitional period. The Centers for Medicare & Medicaid Services (CMS) must assign payment codes for such devices within three months of FDA approval. The CMS must also establish a process to allow for continued coverage after the transitional period has expired, taking into account any additional evidence or data the CMS deems necessary. The CMS must also provide for temporary and, where appropriate, permanent Medicare coverage of breakthrough devices for which there is no existing benefit category (i.e., classification).
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
22 June 2021
Referred
Referred to the Subcommittee on Health.
Source: Committee
22 June 2021
Introduced
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Source: IntroReferral
22 June 2021
Introduced
Introduced in House
Source: IntroReferral
22 June 2021
Introduced
Introduced in House
Source: IntroReferral
23 June 2021
Referred
Referred to the Subcommittee on Health.
Source: Committee
Votes
No vote records are attached yet.
Versions
- Introduced in House · 22 June 2021 · Download file
Documents
3 official files
Introduced in House (text)
This file cannot be previewed here. Use View or Download.
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in House (text)
Introduced in House · EN · 22 June 2021
Introduced in House (PDF)
Introduced in House · EN · 22 June 2021
ViewDownloadOpen at official source
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in House
summary · EN · 22 June 2021
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Sponsors
- Rep. DelBene, Suzan K. [D-WA-1] · D · Sponsor
- Rep. Walorski, Jackie [R-IN-2] · R · Sponsor
- Rep. Cárdenas, Tony [D-CA-29] · D · Sponsor
- Rep. Bilirakis, Gus M. [R-FL-12] · R · Sponsor
- Rep. Sewell, Terri A. [D-AL-7] · D · Sponsor
- Rep. Upton, Fred [R-MI-6] · R · Sponsor
- Rep. Suozzi, Thomas R. [D-NY-3] · D · Cosponsor
- Rep. Houlahan, Chrissy [D-PA-6] · D · Cosponsor
- Rep. Dunn, Neal P. [R-FL-2] · R · Cosponsor
- Rep. Bera, Ami [D-CA-6] · D · Cosponsor
- Rep. McGovern, James P. [D-MA-2] · D · Cosponsor
- Rep. Boyle, Brendan F. [D-PA-2] · D · Cosponsor
- Rep. Correa, J. Luis [D-CA-46] · D · Cosponsor
- Rep. Wenstrup, Brad R. [R-OH-2] · R · Cosponsor
- Rep. Crenshaw, Dan [R-TX-2] · R · Cosponsor
- Rep. Schrier, Kim [D-WA-8] · D · Cosponsor
- Rep. Wild, Susan [D-PA-7] · D · Cosponsor
- Rep. Pappas, Chris [D-NH-1] · D · Cosponsor
- Rep. Peters, Scott H. [D-CA-50] · D · Cosponsor
- Rep. Craig, Angie [D-MN-2] · D · Cosponsor
- Rep. McKinley, David B. [R-WV-1] · R · Cosponsor
- Rep. Kelly, Mike [R-PA-16] · R · Cosponsor
- Rep. Lieu, Ted [D-CA-36] · D · Cosponsor
- Rep. Aguilar, Pete [D-CA-33] · D · Cosponsor
- Rep. Cheney, Liz [R-WY-At Large] · R · Cosponsor
- Rep. Emmer, Tom [R-MN-6] · R · Cosponsor
- Rep. Miller, Carol D. [R-WV-1] · R · Cosponsor
- Rep. Steel, Michelle [R-CA-48] · R · Cosponsor
- Rep. Dean, Madeleine [D-PA-4] · D · Cosponsor
- Rep. Smucker, Lloyd [R-PA-11] · R · Cosponsor
- Rep. Joyce, John [R-PA-13] · R · Cosponsor
- Rep. Smith, Jason [R-MO-8] · R · Cosponsor
- Rep. Lamb, Conor [D-PA-17] · D · Cosponsor
- Rep. Auchincloss, Jake [D-MA-4] · D · Cosponsor
- · hsif00 · Standing
- · hswm00 · Standing
Related records
- related to ← Cures 2.0 Act
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/117th-congress/house-bill/4043
- Open data entity: https://api.congress.gov/v3/bill/117/hr/4043
- us · 117-hr-4043 · source updated 3 January 2025